Further Drawdown of T1 of the Redeemable Convertible Notes
Osteopore Ltd
Key points
- Osteopore draws down additional A$1 million from Tranche 1 of redeemable convertible notes
- Funds to be used for ordinary business operations and future developments
- Subscription agreement with Advance Opportunities Fund and Advance Opportunities Fund I
Full summary
Osteopore Limited, a global leader in 3D-printed biomimetic and bioresorbable implants, has announced that it has drawn down a further A$1 million from Tranche 1 of the redeemable convertible notes it entered into with Advance Opportunities Fund and Advance Opportunities Fund I. This follows the initial drawdown of A$2 million from Tranche 1 that was announced on 14 February 2025. The total amount raised from Tranche 1 now stands at A$3 million, with the funds to be used for the company's ordinary business operations and future developments, projects, and investments as opportunities arise. Osteopore's regenerative medicine products, which utilize 3D-printed biomimetic and bioresorbable materials, are designed to stimulate natural bone healing and reduce post-surgery complications associated with permanent bone implants.